Development fo a novel treatment for asthma: the identification of lead small molecule antagonists of the IL-13/IL-13 re

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/305538

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

In developed countries Asthma ranks among the most common chronic illnesses. Over two million Australians now have this condition and the cost to our community is estimated to be in excess of $720 million per annum. In 1996 researchers at The Walter and Eliza Hall Institute discovered a new member of the cytokine receptor family, IL-13Ra1, which further research has strongly implicated in the pathology of this disease. The main goal of the proposed research is to discover small molecule antagonists of IL-13Ra1 and to identify those suitable for development as novel asthma therapeutics.

Funded Activity Details

Start Date: 01-01-2004

End Date: 01-01-2004

Funding Scheme: NHMRC Development Grants

Funding Amount: $99,750.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical and Health Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Asthma | Cytokine receptor | Drug development

Related Links